Alzheimer's Solutions Conference - June 3

Bringing together scientists, physicians, patient families & funders in a collaborative effort to explore and advance innovations in the battle against Alzheimer's!

ALZHEIMER'S SOLUTIONS CONFERENCE 2019 PRELIMINARY PROGRAM:

All Monday June 3rd sessions will be held at the University of the Sciences / McNeil Science and Technology Center, located at 4308 Woodland Ave, Philadelphia, PA 19026.

Sunday, June 2, 2019
7:00pm - 9:00pm VIP Reception at New Deck Tavern - 3408 Sansom St, Philadelphia, PA 19104
Monday, June 3, 2019
7:45am - 8:50am Registration & Breakfast
9:00am - 9:05am Opening remarks by Max Tokarsky,
Founder & CEO of InvestAcure
9:05am - 9:15am Optimism and Lessons: Advances in Alzheimer’s Diagnostics and Treatment
Howard Fillit, MD, Founding Executive Director and Chief Science Officer, ADDF
9:15am - 9:30am Solving The Alzheimer's Puzzle: A Portfolio Approach to Clinical Trials
George Perry, PhD, Professor of Biology & Chemistry, Chief Scientist, Brain Health Consortium, The University of Texas at San Antonio
Session I: Alzheimer's Research Progress & Early Detection Breakthroughs
9:30am - 9:45am The Case for Combination Therapy in Alzheimer's Disease
Hugo Geerts, PhD, Chief Scientist, In Silico Biosciences, Inc.
9:45am - 10:00am Accurate Alzheimer's Diagnostics in the Palm of Your Hand
Rhoda Au, PhD, Professor of Anatomy & Neurobiology, Boston University Schools of Medicine
10:00am - 10:15am LymPro: The Immune-based Blood Test for Alzheimer’s
Paula Trzepacz, MD, Scientific Advisor for Alzheimer’s Diagnostics, Todos Medical
10:15am - 10:30am Panel Discussion and Q & A
10:30am - 11:00am Break
Session II. From News Headlines to Patients: Clinical Trial Ready Drugs (Part 1)
11:00am - 11:15am NDX-1017: Restoring Lives by Advancing Bold Therapies, Thoughtfully and Urgently
Leen Kawas, PhD, President & CEO, Athira Pharma
11:15am - 11:30am The Yin and Yang of the Brain: How to Equilibrate a Malfunctioning Brain Using Epigenetics
Tamara Maes, PhD, Chief Scientific Officer, Oryzon Genomics
11:30am - 11:45am Bryostatin: A Natural Compound from the Depths of the Ocean to Help Restore Neural Pathways and Reverse Alzheimer's Memory Loss
Dan Alkon, MD, President & Chief Scientific Officer, Neurotrope
11:45am - 12:00pm BPN14770: A Novel Approach to Preserve Neuronal Connections and Prevent Memory Loss in Alzheimer's Patients
Mark E. Gurney, PhD, MBA, Chairman & CEO, Tetra Discovery Partners Inc.
12:00pm - 12:15pm AGB-101: A Novel Approach to Stop Alzheimer's at its Earliest Signs
Sharon Rosenzweig-Lipson, PhD, Vice President of Research and Development, AgeneBio.
12:15pm - 12:30pm Panel Q & A
12:30pm - 1:30pm Lunch
Session III. From News Headlines to Patients: Clinical Trial Ready Drugs (Part 2)
1:30pm - 1:45pm Alz-801 Phase 3 -Ready Program: A Targeted Therapy for Alzheimer's Disease
Martin Tolar, MD, PhD, Founder, President & CEO, Alzheon, Inc.
1:45pm - 2:00pm Troriluzole: Novel Drug that Targets Glutamate as a Potential Treatment for Alzheimer's Disease
Irfan Qureshi, MD, Executive Director of Neurology, Biohaven Pharmaceuticals
2:00pm - 2:15pm Memtin - Patented Hormone Replacement Therapy for Slowing Cognitive Decline in Alzheimer’s Disease and Other Dementias
Nik Tezapsidis, PhD, President & CEO, Neurotez, Inc.
2:15pm - 2:30pm Hitting 3 Birds with One Pill: How SM07883 May Prevent Tau, Amyloid and Inflammation in Alzheimer’s Disease
David Herman, PhD, Director, Medical Affairs and Benoît Melchior, PhD, Director, Biology, Samumed LLC
2:30pm - 2:45pm Panel Discussion and Q & A
2:45pm - 3:15pm Break
Session IV. Solving the Investment Valley of Death and Turning Science Into Cure
3:15pm - 3:30pm Alzheimer's: What if Drug Companies Were Owned by Millions Waiting for a Cure? - The Spare Change Investment Solution
Max Tokarsky, Founder & CEO of InvestAcure, PBC
3:30pm - 3:45pm A Solution to the ‘Valley of Death’ in Alzheimer’s Finance
David Weild, Chairman & CEO, Weild & Co, Co-founder & Vice Chairman, InvestAcure, PBC
3:45pm - 4:00pm Securing Alzheimer's Investment: From Spare Change to $1 Billion
Ken Abramowitz, Co-Founder & Managing General Partner, NGN Capital, Chief Investment Officer, InvestAcure, PBC
4:00pm - 4:15pm Panel Discussion and Q & A
4:15pm - 4:45pm Break
Session V. Lifestyle Interventions: Nutrition, Meditation & Physical Exercise
4:45pm - 5:00pm Science of Prevention: The 5 Alzheimer’s Busting Habits
Adeboye Adejare, PhD, Professor of Pharmaceutical Sciences, University of the Sciences
5:00pm - 5:15pm African Dance: Can It Be a Culturally Salient Way to Lower the Risk of Alzheimer’s Disease and Related Dementias for African Americans?
Kathryn Jedrziewski, PhD, Deputy Director of the Institute on Aging (IOA), University of Pennsylvania
5:15pm - 5:30pm MapHabit: The Secret Sauce for Memory Health
Matt Golden, Co-Founder & CEO, MapHabit
5:30pm - 5:45pm Panel Discussion and Q & A
5:45pm - 8:00pm Together We Cure! Closing Reception